SCHEMBL24209682

SCHEMBL24209682

O=C(O)c1ccc(-n2nnnc2SCC(=O)c2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.71
TSHR P16473 3/20 0.71
HPGD P15428 2/20 0.71
ALDH1A1 P00352 6/20 0.65
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
POLB P06746 4/20 0.65
MAPK1 P28482 3/20 0.64
PPARG P37231 1/20 0.64
NPSR1 Q6W5P4 1/20 0.62
CPB1 P15086 1/20 0.61
LMNA P02545 3/20 0.60
RAB9A P51151 2/20 0.60
NPC1 O15118 1/20 0.60
ALPL P05186 3/20 0.60
ALPG P10696 3/20 0.60
KDM4E B2RXH2 2/20 0.60
GAA P10253 2/20 0.60
RECQL P46063 2/20 0.60
THRB P10828 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21951986 0.96 MAPT (0.71) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL24209727 0.94 HPGD (0.67) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL5592639 0.92 ALDH1A1 (0.76) MAPTTSHRALDH1A1MEN1KMT2A
SCHEMBL21952082 0.90 MAPT (0.64) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL21952058 0.90 MAPT (0.64) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL21952054 0.90 MAPT (0.64) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL24209661 0.90 MAPT (0.64) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL24209664 0.90 ALPL (0.73) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL24209657 0.90 MAPT (0.82) MAPTTSHRHPGDALDH1A1MEN1
SCHEMBL21952033 0.90 MEN1 (0.73) MAPTTSHRHPGDALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 US disclosed
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 US disclosed
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS FUND PROFESOR NOVOA SANTOS (ES) 2022-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER XIAP, UBQLN1, MDM2 MAPT 1710/4885TSHR 4635/4885HPGD 2761/4885
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS CHUK, HIPK3, HIPK1 MAPT 3296/4885TSHR 4382/4885HPGD 1570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.